Positron emission tomography/computed tomography (PET/CT) with 18F-2-Fluoro-2-deoxyglucose (18F-FDG), a noninvasive and functional imaging method, has been widely used for evaluating outcome for patients with NSCLC and has a powerful ability to predict the mutation status of EGFR in NSCLC (Berghmans et al., 2008; Zhang et al., 2020). This evidence concerns the gene EGFR and non-small cell lung carcinoma.